Antisense molecules: A promising new therapy for atopic dermatitis

TL;DR

Antisense molecules offer a new way to treat atopic dermatitis by targeting RNA, potentially modifying the disease rather than just managing symptoms.

Contribution

This paper reviews the emerging role of antisense therapy in atopic dermatitis and its potential as a disease-modifying treatment.

Findings

Antisense molecules can target mRNA and non-coding RNAs involved in AD pathogenesis.

Early studies and clinical trials show promising results for antisense-based therapies in AD.

The skin's accessibility makes it suitable for antisense modulation.

Abstract

Atopic dermatitis (AD) is a common chronic inflammatory skin disorder affecting all age groups, especially children, with a prevalence of up to 20% globally. AD remains burdensome and incurable with current therapeutic strategies—ranging from trigger avoidance and skincare to medication—primarily address symptoms rather than disease modification, underscoring the imperative for innovative therapeutic paradigms. RNA-targeted therapies, particularly antisense molecules, have emerged as a transformative approach in precision medicine, with proven clinical success in diseases such as spinal muscular atrophy and familial chylomicronemia syndrome. These therapeutics achieve post-transcriptional regulation unattainable by conventional therapies, enabling direct targeting of messenger RNA (mRNA) and regulatory non-coding RNAs (ncRNAs) implicated in disease pathogenesis. Furthermore, skin is better suited to the antisense modulation due to the relatively easy access to target cells. Numerous studies have explored antisense-based targeting of key drivers in AD progression, yielding promising proof-of-concept results and prompting several early-stage clinical trials. This modality represents a paradigm shift in AD management—one that aligns with the broader revolution in RNA therapeutics reshaping modern medicine. This review critically examines the evolving role of antisense technology in AD, addressing both its mechanistic rationale and the translational challenges that must be overcome to realize its full clinical potential.

Antisense molecule therapy offers a promising, novel approach targeting the molecular roots of atopic dermatitis at the RNA level, aiming for disease modification beyond current symptomatic treatments.Image 1

Figures